1. Volume 43, Issue 2, Pages 138-145 (February 2003)
Prognostic Value of MCM2 Immunoreactivity in Stage T1 Transitional Cell Carcinoma of the Bladder 
Stefan Krüger, Christoph Thorns, Winfried Stöcker, Ewald Müller-Kunert, Andreas Böhle, Alfred C Feller 
European Urology 
Volume 43, Issue 2, Pages (February 2003)
DOI: /S (02)

2. Fig. 1
Aspect of a Biochip after immunohistochemical staining (only a part of the slide is shown). Representative specimens of tumor tissue (size: 2mm×2mm, respectively) are arranged in lines and rows.
European Urology  , DOI: ( /S (02) )

3. Fig. 2
MCM2 immunoreactivity of a G2 papillary transitional cell carcinoma. The positive reaction is indicated by a brown color of the tumor cell nuclei (magnification, 250×).
European Urology  , DOI: ( /S (02) )

4. Fig. 3
Kaplan–Meier curve for recurrence-free survival of 54 stage T1 bladder carcinoma patients with regard to MCM2 expression (cutoff: 60%). Low-level expressors are indicated by a dotted line, high-level expressors by a solid line, and censored data by squares, respectively. A significant difference in survival exists between these two groups (p= by log-rank test).
European Urology  , DOI: ( /S (02) )

5. Fig. 4
Kaplan–Meier curve for progression-free survival of 54 stage T1 bladder carcinoma patients with regard to MCM2 expression (cutoff: 20%). Low-level expressors are indicated by a dotted line, high-level expressors by a solid line, and censored data by squares. A significant difference in survival exists between these two groups (p= by log-rank test).
European Urology  , DOI: ( /S (02) )